Not sure the evidence is there
El Reg referenced two studies. The link to one appears to be broken, but the Singapore study titled "Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore" had this to say:
"As BNT162b2 and mRNA-1273 were recommended over CoronaVac and BBIBP-CorV in Singapore, numbers of severe disease among individuals who received four doses of inactivated whole-virus vaccines or mixed vaccine type were too small for meaningful analysis." So, we may not want to draw too many conclusions from that study.
Another comparative study which is widely referenced is one in Brazil titled "Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study"
June 01, 2022
Here's the link to the article in The Lancet (a major UK medical journal).
It had this to say:
"Effectiveness against hospitalisation or death 14 or more days from vaccine series completion was 81·3% (75·3–85·8) for CoronaVac, 89·9% (83·5–93·8) for ChAdOx1 nCoV-19, 57·7% (−2·6 to 82·5) for Ad26.COV2.S, and 89·7% (54·3–97·7) for BNT162b2."
The vaccines referenced are CoronaVac, Oxford AstraZeneca, Johnson & Johnson, and BioNTech/Pfizer respectively.
In other words, the Johnson & Johnson is not very effective, but CoronaVac seems to be only marginally less effective than Oxford-AstraZeneca or BioNTech-Pfizer in terms of hospitalisation or death.
Efficacy against infection is less impressive, but the same is true for the rest of the vaccines as well.
There are two main components in your immune system which vaccines stimulate. Antibodies prevent infection, but they are short acting (weeks or months at most) and sensitive to changes in variants. T-cells prevent severe hospitalisation or death and are both much longer lasting and far less sensitive to changes in variants.
The big problem in China isn't that their vaccines don't work. The problem is that the older people are the ones who are least likely to have gone out and gotten their jabs and the younger people are the most likely, while in many Western countries it's the other way around.
What this suggests it that there will be plenty of symptomatic infections among the general population, but hospitalisation and severe disease is likely to be mainly in people who are unvaccinated.
Since in China the unvaccinated are mainly the elderly who are much less likely to be part of the working population, the economic effects are at best unclear.
Among the working population there may be plenty of short term work absences due to mild illness, but we saw the same in Western countries a year ago when the omicron wave swept through and that didn't shut down the economies there.
I'm making no predictions here, just pointing out that it's a bit soon to be predicting pandemic induced chaos in the Chinese economy as the evidence isn't there yet.
That doesn't mean to say that there won't be plenty of unfortunate deaths, but the kit you've got on order from China may arrive safely after all.